The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Providing a PLATFORM: first results for liso-cel plus durvalumab in R/R B-cell NHL
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the first results of the PLATFORM trial (NCT03310619). She discusses the safety of lisocabtagene maraleucel given with durvalumab to patients with relapsed/refractory aggressive B-cell non-Hodgkin lympoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
